{
    "clinical_study": {
        "@rank": "26813", 
        "acronym": "DLTCAM", 
        "arm_group": [
            {
                "arm_group_label": "Spectacles", 
                "arm_group_type": "Active Comparator", 
                "description": "Spectacles are the most common lens treatment to correct myopia. This arm is set to be as a control group for the other two arms. Myopia patients who enter in this group will wear a normal pair of glasses after the baseline examinations (axial length, refraction...)."
            }, 
            {
                "arm_group_label": "Myovison", 
                "arm_group_type": "Active Comparator", 
                "description": "Myovision is a kind of specially designed, commercially available spectacle lenses that could control the peripheral refraction of myopia patients. Latest studies have changed the understanding of myopia--correcting both central and peripheral vision during lens treatment is indicating to be an effective way of slowing down eye growth. Patients who entered this group will wear a pair of Myovision after baseline examinations."
            }, 
            {
                "arm_group_label": "Ortho-K", 
                "arm_group_type": "Active Comparator", 
                "description": "Orthokeratology has recently been reported as an effective way to control eye growth for myopia adolescents. Patents who enter this group will wear ortho-K lenses during sleep after baseline examinations."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the efficacy of different lens treatments (normal\n      spectacle lens, ortho-K, & Myovision) on myopia control in Chinese adolescent patients."
        }, 
        "brief_title": "Efficacy Study of Different Lens Treatments on Chinese Adolescent Myopia", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Progressive Myopia", 
        "condition_browse": {
            "mesh_term": [
                "Myopia", 
                "Myopia, Degenerative"
            ]
        }, 
        "detailed_description": {
            "textblock": "Different lens treatments include normal spectacle lens, orthokeratology, and  Myovision (a\n      specially designed spectacle lens commercially available with peripheral defocus controlled\n      as relative myopia).\n\n      This study is to evaluate the efficacy of these three methods in controlling myopia\n      progression. Until now, there is no sufficient clinical evidences to compare different lens\n      treatments."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adolescent myopia patients\n\n          -  Myopic refraction between -1.00D and -4.50D\n\n          -  Astigmatism equal or less than -1.50D\n\n          -  Normal break up time of tear film (BUT > 10s)\n\n        Exclusion Criteria:\n\n          -  Existence of any ocular diseases except ametropia\n\n          -  Hyperopia\n\n          -  Severe dry eye"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "15 Years", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02001415", 
            "org_study_id": "Z131107002213127"
        }, 
        "intervention": [
            {
                "arm_group_label": "Spectacles", 
                "description": "Normal spectacle lenses were used to correct myopia as the control group.", 
                "intervention_name": "Spectacles", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Myovison", 
                "description": "Myovision is a kind of specially designed spectacle glasses that could control the peripheral refraction of myopia patients. It is commercially available.", 
                "intervention_name": "Myovision", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Ortho-K", 
                "description": "Orthokeratology lenses.", 
                "intervention_name": "Orthokeratology", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Progressive Myopia", 
            "Contact Lenses", 
            "Spectacles"
        ], 
        "lastchanged_date": "June 4, 2014", 
        "location": {
            "contact": {
                "email": "medisaker@gmail.com", 
                "last_name": "Kai Wang, Dr."
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100044"
                }, 
                "name": "Ophthalmology Department of Peking University People's Hospital"
            }, 
            "investigator": {
                "last_name": "Kai Wang, Dr.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "Randomized Controlled Trial of Different Lens Treatments on Chinese Adolescent Myopia", 
        "overall_contact": {
            "email": "medisaker@gmail.com", 
            "last_name": "Kai Wang, Dr.", 
            "phone": "+86-13810097881"
        }, 
        "overall_contact_backup": {
            "last_name": "Xi Rong Wu, Dr."
        }, 
        "overall_official": {
            "affiliation": "Peking University People's Hospital", 
            "last_name": "Kai Wang, Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "China: Ministry of Health", 
                "China: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Ocular axial length (AL), which increases with age, will be measured 3 times by an IOLMaster. The first AL examination was considered as the baseline data, and will be repeated 6 and 12 months later.", 
            "measure": "Change of Ocular Axial Length", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 6 months, 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02001415"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Spherical Equivalent Refraction (SER), which usually changes from time to time, will be measured 3 times by an open field auto-refractometer. The first SER examination was considered as the baseline data, and will be repeated 6 and 12 months later.", 
            "measure": "Change of Spherical Equivalent Refraction", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 6 months, 12 months"
        }, 
        "source": "Peking University People's Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking University People's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}